AJOVY® is a monoclonal antibody that selectively binds to CGRP1

How AJOVY® works

AJOVY® is a humanised monoclonal antibody, targeting CGRP.1

Patients with migraine have increased levels of CGRP, a neuropeptide that presents in both the central and peripheral nervous system.2,3 When CGRP binds to its receptor, a cascade of events result, which contributes to neurogenic inflammation that is associated with migraine pain.2,4 This involves mast cell degranulation, vasodilation, and protein extravasation.5 AJOVY® selectively targets the CGRP ligand, which is believed to block this cascade of events, thereby preventing the activation of the trigeminal system.1,4

CGRP plays an important role in the pathophysiology of migraine.4

CGRP, calcitonin gene-related peptide.

Suggestions to explore next

Continue to Efficacy page of AJOVY

Significantly more migraine-free days vs placebo1,6-9

Efficacy of AJOVY®
Continue to Dosing flexibility page of AJOVY

Flexibility to help you meet your patients' needs1,9

Flexibility of ajovy®
Continue to Safety page of AJOVY

A generally well-tolerated treatment choice1,6-9

safety profile of ajovy®

Better quality of life with AJOVY® vs placebo10-12

Quality of life data for ajovy®